{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:41:24Z","timestamp":1785008484302,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH192"],"award-info":[{"award-number":["ZR2023QH192"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022QH354"],"award-info":[{"award-number":["ZR2022QH354"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10495-026-02318-x","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T17:03:52Z","timestamp":1774199032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insulin-like growth factor binding protein-3 serves as a biomarker for resistance to enzalutamide in prostate cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Ze","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzheng","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"key":"2318_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"2318_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","volume":"140","author":"AA Shafi","year":"2013","unstructured":"Shafi AA, Yen AE, Weigel NL (2013) Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther 140:223\u2013238","journal-title":"Pharmacol Ther"},{"key":"2318_CR3","doi-asserted-by":"publisher","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","volume":"23","author":"HI Scher","year":"2005","unstructured":"Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253\u20138261","journal-title":"J Clin Oncol"},{"key":"2318_CR4","doi-asserted-by":"crossref","unstructured":"Crona DJ, Whang YE (2017) Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel), 9","DOI":"10.3390\/cancers9060067"},{"key":"2318_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/CU9.0000000000000300","volume":"19","author":"M Sands","year":"2025","unstructured":"Sands M, Adams S, Lee J, Li M, Wang M, Walsh T, Leon L, Zablah A, Haerens M, Liu Z, Li J (2025) the interconnection between androgen receptor and dna damage response pathways in prostate cancer. Curr Urol 19:376\u2013387","journal-title":"Curr Urol"},{"key":"2318_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41467-024-44686-5","volume":"15","author":"S Panja","year":"2024","unstructured":"Panja S, Truica MI, Yu CY, Saggurthi V, Craige MW, Whitehead K, Tuiche MV, Al-Saadi A, Vyas R, Ganesan S, Gohel S, Coffman F, Parrott JS, Quan S, Jha S, Kim I, Schaeffer E, Kothari V, Abdulkadir SA, Mitrofanova A (2024) Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Nat Commun 15:352","journal-title":"Nat Commun"},{"key":"2318_CR7","doi-asserted-by":"crossref","unstructured":"Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z (2020) Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance, vol 117. Proc Natl Acad Sci U S A, pp 12315\u201312323","DOI":"10.1073\/pnas.1922207117"},{"key":"2318_CR8","first-page":"189","volume":"2","author":"EB Blatt","year":"2019","unstructured":"Blatt EB, Raj GV (2019) Molecular mechanisms of enzalutamide resistance in prostate cancer. Cancer Drug Resist 2:189\u2013197","journal-title":"Cancer Drug Resist"},{"key":"2318_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790","journal-title":"Science"},{"key":"2318_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1158\/1078-0432.CCR-18-1431","volume":"25","author":"EA Mostaghel","year":"2019","unstructured":"Mostaghel EA, Zhang A, Hernandez S, Marck BT, Zhang X, Tamae D, Biehl HE, Tretiakova M, Bartlett J, Burns J, Dumpit R, Ang L, Matsumoto AM, Penning TM, Balk SP, Morrissey C, Corey E, True LD, Nelson PS (2019) Contribution of adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer. Clin Cancer Res 25:426\u2013439","journal-title":"Clin Cancer Res"},{"key":"2318_CR11","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin PS, Nelson, L.A., Garraway (2015) C.L. Sawyers, A.M. Chinnaiyan, Integrative clinical genomics of advanced prostate cancer, Cell, 161 1215\u20131228"},{"key":"2318_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298\u2013305","journal-title":"Nat Med"},{"key":"2318_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239\u2013243","journal-title":"Nature"},{"key":"2318_CR14","first-page":"149","volume":"63","author":"T Hara","year":"2003","unstructured":"Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M (2003) Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149\u2013153","journal-title":"Cancer Res"},{"key":"2318_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69:16\u201322","journal-title":"Cancer Res"},{"key":"2318_CR16","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","volume":"69","author":"Z Guo","year":"2009","unstructured":"Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305\u20132313","journal-title":"Cancer Res"},{"key":"2318_CR17","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1158\/0008-5472.CAN-14-3602","volume":"75","author":"CL Hsieh","year":"2015","unstructured":"Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW (2015) PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. Cancer Res 75:1944\u20131948","journal-title":"Cancer Res"},{"key":"2318_CR18","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1158\/1078-0432.CCR-15-2901","volume":"22","author":"YC Yang","year":"2016","unstructured":"Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD (2016) Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res 22:4466\u20134477","journal-title":"Clin Cancer Res"},{"key":"2318_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155:1309\u20131322","journal-title":"Cell"},{"key":"2318_CR20","doi-asserted-by":"publisher","first-page":"e3007","DOI":"10.1038\/cddis.2017.417","volume":"8","author":"Q Liu","year":"2017","unstructured":"Liu Q, Tong D, Liu G, Xu J, Do K, Geary K, Zhang D, Zhang J, Zhang Y, Li Y, Bi G, Lan W, Jiang J (2017) Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1\/STAT3 axis-regulated EMT. Cell Death Dis 8:e3007","journal-title":"Cell Death Dis"},{"key":"2318_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/0008-5472.CAN-15-2078","volume":"76","author":"SK Martin","year":"2016","unstructured":"Martin SK, Pu H, Penticuff JC, Cao Z, Horbinski C, Kyprianou N (2016) Multinucleation and mesenchymal-to-epithelial transition alleviate resistance to combined cabazitaxel and antiandrogen therapy in advanced prostate cancer. Cancer Res 76:912\u2013926","journal-title":"Cancer Res"},{"key":"2318_CR22","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1158\/0008-5472.CAN-16-2169","volume":"77","author":"L Miao","year":"2017","unstructured":"Miao L, Yang L, Li R, Rodrigues DN, Crespo M, Hsieh JT, Tilley WD, de Bono J, Selth LA (2017) Disrupting androgen receptor signaling induces snail-mediated epithelial-mesenchymal plasticity in prostate cancer. Cancer Res 77:3101\u20133112","journal-title":"Cancer Res"},{"key":"2318_CR23","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1038\/s41467-018-07411-7","volume":"9","author":"H Geng","year":"2018","unstructured":"Geng H, Xue C, Mendonca J, Sun XX, Liu Q, Reardon PN, Chen Y, Qian K, Hua V, Chen A, Pan F, Yuan J, Dang S, Beer TM, Dai MS, Kachhap SK, Qian DZ (2018) Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen\/AR-targeted therapy. Nat Commun 9:4972","journal-title":"Nat Commun"},{"key":"2318_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.01.018","volume":"35","author":"M Reina-Campos","year":"2019","unstructured":"Reina-Campos M, Linares JF, Duran A, Cordes T, L\u2019Hermitte A, Badur MG, Bhangoo MS, Thorson PK, Richards A, Rooslid T, Garcia-Olmo DC, Nam-Cha SY, Salinas-Sanchez AS, Eng K, Beltran H, Scott DA, Metallo CM, Moscat J, Diaz-Meco MT (2019) Increased serine and one-carbon pathway metabolism by pkclambda\/iota deficiency promotes neuroendocrine prostate cancer. Cancer Cell 35:385\u2013400e389","journal-title":"Cancer Cell"},{"key":"2318_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbe DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L, Goodrich DW (2017) Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355:78\u201383","journal-title":"Science"},{"key":"2318_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/CU9.0000000000000288","volume":"19","author":"Y Jin","year":"2025","unstructured":"Jin Y, Bai Z, Wang G, Zhang Y, Chen J (2025) Applications and prospects of spatial transcriptomics in prostate cancer research: a narrative review. Curr Urol 19:303\u2013308","journal-title":"Curr Urol"},{"key":"2318_CR27","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin MA (2011) Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 1:487\u2013495","journal-title":"Cancer Discov"},{"key":"2318_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jcmgh.2020.06.006","volume":"10","author":"M Mari","year":"2020","unstructured":"Mari M (2020) IGFBP-3: So Much More Than an IGF1\/2 Binding Protein. Cell Mol Gastroenterol Hepatol 10:643\u2013644","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2318_CR29","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1096\/fj.11-198598","volume":"26","author":"M Natsuizaka","year":"2012","unstructured":"Natsuizaka M, Naganuma S, Kagawa S, Ohashi S, Ahmadi A, Subramanian H, Chang S, Nakagawa KJ, Ji X, Liebhaber SA, Klein-Szanto AJ, Nakagawa H (2012) Hypoxia induces IGFBP3 in esophageal squamous cancer cells through HIF-1alpha-mediated mRNA transcription and continuous protein synthesis. FASEB J 26:2620\u20132630","journal-title":"FASEB J"},{"key":"2318_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12967-023-04701-7","volume":"21","author":"C Shen","year":"2023","unstructured":"Shen C (2023) ID1 and IGFBP3: roles in cellular senescence, cardiac development, angiogenesis and cancer diagnosis. J Transl Med 21:797","journal-title":"J Transl Med"},{"key":"2318_CR31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10549-010-1277-1","volume":"127","author":"AH Rosendahl","year":"2011","unstructured":"Rosendahl AH, Hietala M, Henningson M, Olsson H, Jernstrom H (2011) IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families. Breast Cancer Res Treat 127:785\u2013794","journal-title":"Breast Cancer Res Treat"},{"key":"2318_CR32","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/sj.ki.5001805","volume":"70","author":"AH Rosendahl","year":"2006","unstructured":"Rosendahl AH, Forsberg G (2006) IGFBP-3 augment transforming growth factor-beta actions in human renal carcinoma cells. Kidney Int 70:1584\u20131590","journal-title":"Kidney Int"},{"key":"2318_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3171\/2018.8.JNS181217","volume":"132","author":"CH Chen","year":"2020","unstructured":"Chen CH, Chen PY, Lin YY, Feng LY, Chen SH, Chen CY, Huang YC, Huang CY, Jung SM, Chen LY, Wei KC (2020) Suppression of tumor growth via IGFBP3 depletion as a potential treatment in glioma. J Neurosurg 132:168\u2013179","journal-title":"J Neurosurg"},{"key":"2318_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cen.13499","volume":"88","author":"YX Chan","year":"2018","unstructured":"Chan YX, Alfonso H, Paul Chubb SA, Ho KKY, Gerard Fegan P, Hankey GJ, Golledge J, Flicker L, Yeap BB (2018) Higher IGFBP3 is associated with increased incidence of colorectal cancer in older men independently of IGF1. Clin Endocrinol (Oxf) 88:333\u2013340","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2318_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1476-4598-11-9","volume":"11","author":"I Regel","year":"2012","unstructured":"Regel I, Eichenmuller M, Joppien S, Liebl J, Haberle B, Muller-Hocker J, Vollmar A, von Schweinitz D, Kappler R (2012) IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Mol Cancer 11:9","journal-title":"Mol Cancer"},{"key":"2318_CR36","doi-asserted-by":"publisher","first-page":"140310","DOI":"10.1016\/j.ijbiomac.2025.140310","volume":"300","author":"N Wu","year":"2025","unstructured":"Wu N, Sun Q, Yang L, Sun H, Zhou Z, Hu Q, Li C, Wang D, Zhang L, Hu Y, Cong X (2025) HDAC3 and Snail2 complex promotes melanoma metastasis by epigenetic repression of IGFBP3. Int J Biol Macromol 300:140310","journal-title":"Int J Biol Macromol"},{"key":"2318_CR37","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1038\/s41388-022-02426-3","volume":"41","author":"L Tian","year":"2022","unstructured":"Tian L, Xie X, Das U, Chen Y, Sun Y, Liu F, Lu H, Nan P, Zhu Y, Gu X, Deng H, Xie J, Zhao X (2022) Forming cytoplasmic stress granules PURalpha suppresses mRNA translation initiation of IGFBP3 to promote esophageal squamous cell carcinoma progression. Oncogene 41:4336\u20134348","journal-title":"Oncogene"},{"key":"2318_CR38","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","volume":"81","author":"L Gao","year":"2021","unstructured":"Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, Hu J, Wang X, Wang X, Su P, Chen S, Qu S, Shi B, Xiong X, Chen W, Dong X, Han B (2021) KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer. Cancer Res 81:1026\u20131039","journal-title":"Cancer Res"},{"key":"2318_CR39","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12967-023-04146-y","volume":"21","author":"Z Li","year":"2023","unstructured":"Li Z, Tao Y, Gao Z, Peng S, Lai Y, Li K, Chen X, Huang H (2023) SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion. J Transl Med 21:303","journal-title":"J Transl Med"},{"key":"2318_CR40","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41588-019-0456-1","volume":"51","author":"H Fang","year":"2019","unstructured":"Fang H, Consortium U-D, De Wolf H, Knezevic B, Burnham KL, Osgood J, Sanniti A, Lledo Lara A, Kasela S, De Cesco S, Wegner JK, Handunnetthi L, McCann FE, Chen L, Sekine T, Brennan PE, Marsden BD, Damerell D, O\u2019Callaghan CA, Bountra C, Bowness P, Sundstrom Y, Milani L, Berg L, Gohlmann HW, Peeters PJ, Fairfax BP, Sundstrom M, Knight JC (2019) A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat Genet 51:1082\u20131091","journal-title":"Nat Genet"},{"key":"2318_CR41","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep 18:248\u2013262","journal-title":"Cell Rep"},{"key":"2318_CR42","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, Cheng JN, Sun H, Guan Y, Xia X, Yang L, Yi X, Wan YY, Wang H, He J, Futreal PA, Li QJ, Zhu B (2018) Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun 9:5361","journal-title":"Nat Commun"},{"key":"2318_CR43","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1002\/ctm2.191","volume":"10","author":"Z Li","year":"2020","unstructured":"Li Z, Wang Q, Peng S, Yao K, Chen J, Tao Y, Gao Z, Wang F, Li H, Cai W, Lai Y, Li K, Chen X, Huang H (2020) The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling. Clin Transl Med 10:e191","journal-title":"Clin Transl Med"},{"key":"2318_CR44","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15:701\u2013711","journal-title":"Nat Rev Cancer"},{"key":"2318_CR45","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/onc.2012.264","volume":"32","author":"S Grkovic","year":"2013","unstructured":"Grkovic S, O\u2019Reilly VC, Han S, Hong M, Baxter RC, Firth SM (2013) IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene 32:2412\u20132420","journal-title":"Oncogene"},{"key":"2318_CR46","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s12276-023-01142-6","volume":"56","author":"X Li","year":"2024","unstructured":"Li X, Zhang CC, Lin XT, Zhang J, Zhang YJ, Yu HQ, Liu ZY, Gong Y, Zhang LD, Xie CM (2024) Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma. Exp Mol Med 56:177\u2013191","journal-title":"Exp Mol Med"},{"key":"2318_CR47","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1038\/sj.onc.1207882","volume":"23","author":"YS Chang","year":"2004","unstructured":"Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK, Lee HY (2004) Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 23:6569\u20136580","journal-title":"Oncogene"},{"key":"2318_CR48","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/1097-0215(20001101)88:3<448::AID-IJC18>3.0.CO;2-V","volume":"88","author":"CA Fowler","year":"2000","unstructured":"Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM (2000) Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer 88:448\u2013453","journal-title":"Int J Cancer"},{"key":"2318_CR49","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41419-022-05094-z","volume":"13","author":"X Liu","year":"2022","unstructured":"Liu X, Jin Y, Wan X, Liang X, Wang K, Liu J, Jiang J, Meng B, Han S, Zhou L, Cai S, Zou F (2022) SALIS transcriptionally represses IGFBP3\/Caspase-7-mediated apoptosis by associating with STAT5A to promote hepatocellular carcinoma. Cell Death Dis 13:642","journal-title":"Cell Death Dis"},{"key":"2318_CR50","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.bbrc.2010.12.115","volume":"IGFBP3","author":"K Yoshino","year":"2011","unstructured":"Yoshino K, Motoyama S, Koyota S, Shibuya K, Usami S, Maruyama K, Saito H, Minamiya Y, Sugiyama T, Ogawa J (2011) BAG1 enhance radiation-induced apoptosis in squamous esophageal cancer cells. Biochem Biophys Res Commun IGFBP3:1070\u20131075","journal-title":"Biochem Biophys Res Commun"},{"key":"2318_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1677\/joe.0.1600379","volume":"160","author":"SM Firth","year":"1999","unstructured":"Firth SM, Baxter RC (1999) Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol 160:379\u2013387","journal-title":"J Endocrinol"},{"key":"2318_CR52","doi-asserted-by":"publisher","first-page":"110519","DOI":"10.1016\/j.isci.2024.110519","volume":"27","author":"J Zhao","year":"2024","unstructured":"Zhao J, Fang L, Pu R, Liu W, Cai S, Wang R, Shi Y, Li Z, Zhang Z, Li Z, Cao G (2024) Androgen receptor-induced molecules and androgen contribute synergistically to male-predominance of hepatocellular carcinoma. iScience 27:110519","journal-title":"iScience"},{"key":"2318_CR53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","volume":"18","author":"KT Schmidt","year":"2021","unstructured":"Schmidt KT, Huitema ADR, Chau CH, Figg WD (2021) Resistance to second-generation androgen receptor antagonists in prostate cancer. Nat Rev Urol 18:209\u2013226","journal-title":"Nat Rev Urol"},{"key":"2318_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG (2021) Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 16:223\u2013249","journal-title":"Annu Rev Pathol"},{"key":"2318_CR55","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.xcrm.2022.100613","volume":"3","author":"BA Siddiqui","year":"2022","unstructured":"Siddiqui BA, Subudhi SK, Sharma P (2022) Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 3:100613","journal-title":"Cell Rep Med"},{"key":"2318_CR56","doi-asserted-by":"crossref","unstructured":"Xu P, Yang JC, Chen B, Nip C, Van Dyke JE, Zhang X, Chen HW, Evans CP, Murphy WJ, Liu C (2023) Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. J Immunother Cancer, 11","DOI":"10.1136\/jitc-2022-006581"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02318-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:02:36Z","timestamp":1777633356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2318"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02318-x","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"109"}}